KAKEN PHARMACEUTIAL CO., LTD.
4521科研製薬株式会社
Latest half-year results
First half · fiscal year to 2026-03 · filed 2025-11-13For the first half of the fiscal year to 2026-03: Revenue ¥39.4 billion (-23.4% YoY), Ordinary income ¥0.6 billion (-96.9% YoY), Net income ¥1 billion (-93.1% YoY).
| This period | Year on year | |
|---|---|---|
| Revenue | ¥39.4bn | -23.4% |
| Ordinary profit | ¥607m | -96.9% |
| Net profit to owners | ¥992m | -93.1% |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4521/earnings-releases.
Financials
Japan GAAP · consolidated · fiscal year to 2026-03-31- Revenue
- ¥76.9bn
- Net income
- ¥2.1bn
- ROE
- 1.4%
- Equity ratio
- 82.8%
- Dividend / share
- ¥190
- Employees
- 1,114
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | ¥76.9bn | ¥2.1bn | ¥178.2bn | ¥147.6bn | 1.4% | ¥56.57 | −¥11.1bn |
| 2025-03-31 | ¥94.0bn | ¥13.9bn | ¥193.4bn | ¥152.6bn | 9.4% | ¥365.42 | ¥29.8bn |
| 2024-03-31 | ¥72.0bn | ¥8.0bn | ¥171.6bn | ¥143.8bn | 5.7% | ¥212.67 | ¥2.6bn |
| 2023-03-31 | ¥73.0bn | ¥5.4bn | ¥166.3bn | ¥136.8bn | 4.0% | ¥144.8 | ¥9.3bn |
| 2022-03-31 | ¥76.0bn | ¥9.5bn | ¥165.2bn | ¥138.3bn | 7.0% | ¥251.43 | ¥13.3bn |
Indicators
Computed by us from filings · fiscal year to 2026-03-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | 1.4 | 9.1 |
| Ordinary margin | -0.0027 | 9.5 |
| Equity ratio, % | 82.8 | 92.8 |
| Revenue growth | -0.1825 | 2.9 |
| Net income growth | -0.8463 | 7.9 |
| Operating cash flow / assets | -0.0622 | 6.9 |
Results wording balance: -0.54. Proprietary text method; it describes the wording only and does not interpret context.
Interest example: if all ¥3.9bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥19m. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.
Via /v1/companies/4521/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themSegments, votes and tender offers
Stated in EDINET filings/v1/companies/4521/segments/v1/companies/4521/votingOwnership changes
All companies →- 2026-08-07
Mizuho Bank,Ltd. reduced holdings in KAKEN PHARMACEUTIAL CO., LTD. (4521) to 5.08% from 5.71%.
- 2024-11-26
― cut holdings in KAKEN PHARMACEUTIAL CO., LTD. (4521) to 4.95% from 6.11%, below the 5% threshold.
- 2024-06-26
― raised holdings in KAKEN PHARMACEUTIAL CO., LTD. (4521) to 6.11% from 5.03%.
- 2024-06-05
― states it may make proposals to the management of KAKEN PHARMACEUTIAL CO., LTD. (4521) (first filing).
- 2024-06-05
― disclosed a 5.03% stake in KAKEN PHARMACEUTIAL CO., LTD. (4521), crossing the 5% reporting threshold.
- 2024-03-27
Silchester International Investors LLP cut holdings in KAKEN PHARMACEUTIAL CO., LTD. (4521) to 4.82% from 5.90%, below the 5% threshold.
- 2023-10-12
Silchester International Investors LLP reduced holdings in KAKEN PHARMACEUTIAL CO., LTD. (4521) to 5.90% from 6.95%.
- 2023-09-19
Silchester International Investors LLP reduced holdings in KAKEN PHARMACEUTIAL CO., LTD. (4521) to 6.95% from 8.03%.
- 2022-03-28
Silchester International Investors LLP states it may make proposals to the management of KAKEN PHARMACEUTIAL CO., LTD. (4521) (first filing on record).
- 2022-03-28
Silchester International Investors LLP raised holdings in KAKEN PHARMACEUTIAL CO., LTD. (4521) to 8.03% from 7.03%.
Trades by 5% holders
From the 60-day trade tables in 5% reports| Holder | Period | Net shares | Net % of shares | Avg. filed price | Range |
|---|---|---|---|---|---|
| 株式会社南青山不動産 | 2024-06-10 – 2024-11-19 | +211,300 | +0.45pt | ¥3,830 | ¥3,830–3,830 |
| individual filer | 2024-04-01 – 2024-11-12 | +971,900 | +2.07pt | — | — |
| Silchester International Investors LLP | 2022-01-25 – 2024-03-26 | -1,173,200 | −2.54pt | ¥3,589.73 | ¥3,455–4,222 |
Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4521/trades.
5% filings
Large shareholding reports on 4521| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-08-07 | Mizuho Bank,Ltd. | 5.08% | −0.63pt | — |
| 2024-11-26 | ― | 4.95% | −1.16pt | may make proposals |
| 2024-06-26 | ― | 6.11% | +1.08pt | may make proposals |
| 2024-06-05 | ― | 5.03% | — | may make proposals |
| 2024-03-27 | Silchester International Investors LLP | 4.82% | −1.08pt | may make proposals |
| 2023-10-12 | Silchester International Investors LLP | 5.90% | −1.05pt | may make proposals |
| 2023-09-19 | Silchester International Investors LLP | 6.95% | −1.08pt | may make proposals |
| 2022-03-28 | Silchester International Investors LLP | 8.03% | +1.00pt | may make proposals |
Cross-shareholdings
From the annual report's status of shareholdings- Listed strategic holdings
- 21 issues
- Book value
- ¥18.0bn
- Sold in the year
- ¥3.1bn 5 issues
- Bought in the year
- — — issues
- Mutual, both reports
- 18
- Held by listed cos.
- 21
| Holds | Book value | Shares vs. prior year | Mutual |
|---|---|---|---|
| Fuyo General Lease Co., Ltd. 8424 | ¥3,857m | +200.0% | both reports |
| KYORIN Pharmaceutical Co., Ltd. 4569 | ¥2,635m | 0.0% | both reports |
| KIKKOMAN CORPORATION 2801 | ¥2,152m | -18.5% | both reports |
| TORAY INDUSTRIES,INC. 3402 | ¥1,433m | -55.1% | both reports |
| MEDIPAL HOLDINGS CORPORATION 7459 | ¥1,118m | 0.0% | both reports |
| Mizuho Financial Group, Inc. 8411 | ¥1,044m | -20.0% | stated |
| THE SHIGA BANK,LTD. 8366 | ¥893m | 0.0% | stated |
| SEIKAGAKU CORPORATION 4548 | ¥880m | 0.0% | both reports |
| TORAY INDUSTRIES,INC. 3402 | ¥880m | 0.0% | both reports |
| Nissan Chemical Corporation 4021 | ¥807m | 0.0% | both reports |
Held by: TORAY INDUSTRIES,INC. 3402, KYORIN Pharmaceutical Co., Ltd. 4569, KAJIMA CORPORATION 1812, SEIKAGAKU CORPORATION 4548, Fuyo General Lease Co., Ltd. 8424, KIKKOMAN CORPORATION 2801, Iyogin Holdings,Inc. 5830, Nippon Shinyaku Co.,Ltd. 4516, MEDIPAL HOLDINGS CORPORATION 7459, Nissan Chemical Corporation 4021, IWATANI CORPORATION 8088, The Chiba Bank, Ltd. 8331 and 9 more
Purposes, all holdings and mutual flags via /v1/companies/4521/cross-holdings. Share changes include stock splits.
Major shareholders
As of fiscal year end 2026-03-31| Shareholder | Shares | Ratio |
|---|---|---|
| 日本マスタートラスト信託銀行株式会社(信託口) | 3,891,000 | 10.22% |
| 株式会社日本カストディ銀行(信託口) | 2,170,000 | 5.70% |
| 農林中央金庫 | 1,843,000 | 4.84% |
| ゴールドマン・サックス・アンド・カンパニーレギュラーアカウント | 1,809,000 | 4.75% |
| 株式会社みずほ銀行 | 1,474,000 | 3.87% |
| 東レ株式会社 | 1,147,000 | 3.01% |
| ステート ストリート バンク アンド トラスト カンパニー 505103 | 955,000 | 2.51% |
| ステート ストリート バンク アンド トラスト カンパニー 505001 | 864,000 | 2.27% |
| 杏林製薬株式会社 | 852,000 | 2.24% |
| 科研製薬従業員持株会 | 608,000 | 1.60% |
U.S. funds holding 4521
SEC Form N-PORT, reports to 2026-07-3144 U.S. funds held 2,936,022 shares worth $69.9m.
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Brandes International Small Cap Equity Fund Datum One Series Trust | 548,600 | $13.0m | 1.003% | 2026-06-30 |
| VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND VANGUARD STAR FUNDS | 458,560 | $10.9m | 0.002% | 2026-07-31 |
| College Retirement Equities Fund - Total Global Stock Account College Retirement Equities Fund | 309,379 | $7.3m | 0.005% | 2026-06-30 |
| VANGUARD DEVELOPED MARKETS INDEX FUND VANGUARD TAX-MANAGED FUNDS | 290,406 | $6.9m | 0.002% | 2026-06-30 |
| iShares Core MSCI EAFE ETF iShares Trust | 196,700 | $4.7m | 0.002% | 2026-07-31 |
Up to 25 funds per stock via the API.
Get this as JSON
GET /v1/companies/4521
GET /v1/companies/4521/financials
GET /v1/companies/4521/details
GET /v1/companies/4521/segments
GET /v1/companies/4521/voting
GET /v1/companies/4521/tender-offers
GET /v1/companies/4521/indicators
GET /v1/companies/4521/earnings-releases
GET /v1/events?ticker=4521
GET /v1/companies/4521/trades
GET /v1/companies/4521/cross-holdings
GET /v1/companies/4521/brief